News - Lyonbiopôle

Our news are not all translated. For an exhaustive

list of our news, please consult the French version.

jan. 9^th, 2025

MaaT Pharma announces positive topline results

from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease.

jan. 9^th, 2025

MaaT Pharma announces positive topline results

from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease.

jan. 9^th, 2025

MaaT Pharma announces positive topline results

from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease.

jan. 7^th, 2025

New member : Saxol

They joined us !

jan. 7^th, 2025

New member : Saxol

They joined us !

jan. 7^th, 2025

New member : Saxol

They joined us !

dec. 16^th, 2024

ADOCIA and Tonghua Dongbao Announce the Final Dosing

in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment.

dec. 16^th, 2024

ADOCIA and Tonghua Dongbao Announce the Final Dosing

in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment.

dec. 16^th, 2024

ADOCIA and Tonghua Dongbao Announce the Final Dosing

in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment.

dec. 10^th, 2024

New member : Faiveleytech

They joined us !

dec. 10^th, 2024

New member : Faiveleytech

They joined us !

dec. 10^th, 2024

New member : Faiveleytech

They joined us !

dec. 10^th, 2024

New member : Smartery

They joined us !

dec. 10^th, 2024

New member : Smartery

They joined us !

dec. 10^th, 2024

New member : Smartery

They joined us !

nov. 18^th, 2024

New member : Biwako

They joined us !

nov. 18^th, 2024

New member : Biwako

They joined us !

nov. 18^th, 2024

New member : Biwako

They joined us !

nov. 15^th, 2024

New member : ProteoY

They joined us !

nov. 15^th, 2024

New member : ProteoY

They joined us !

nov. 15^th, 2024

New member : ProteoY

They joined us !

nov. 14^th, 2024

New member : Antibody for Therapy (AbTx)

They joined us !

nov. 14^th, 2024

New member : Antibody for Therapy (AbTx)

They joined us !

nov. 14^th, 2024

New member : Antibody for Therapy (AbTx)

They joined us !

nov. 7^th, 2024

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results

and Announces Management Changes.

nov. 7^th, 2024

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results

and Announces Management Changes.

nov. 7^th, 2024

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results

and Announces Management Changes.

oct. 31^st, 2024

New member : OneOrtho Medical

They joined us !

oct. 31^st, 2024

New member : OneOrtho Medical

They joined us !

oct. 31^st, 2024

New member : OneOrtho Medical

They joined us !

oct. 16^th, 2024

MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial

for MaaT013 to Treat Acute Graft-versus-Host Disease.

oct. 16^th, 2024

MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial

for MaaT013 to Treat Acute Graft-versus-Host Disease.

oct. 16^th, 2024

MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial

for MaaT013 to Treat Acute Graft-versus-Host Disease.

EN only

oct. 16^th, 2024

Adocia announces patenting GLP-1 amylin combination.

using its BioChaperone® platform.

oct. 16^th, 2024

Adocia announces patenting GLP-1 amylin combination.

using its BioChaperone® platform.

oct. 16^th, 2024

Adocia announces patenting GLP-1 amylin combination.

using its BioChaperone® platform.

EN only

oct. 2^nd, 2024

Preclinical Efficacy of Vaxxel’s Intranasal Vaccine Candidate Against Pneumovirus,

Funded by NIAID.

oct. 2^nd, 2024

Preclinical Efficacy of Vaxxel’s Intranasal Vaccine Candidate Against Pneumovirus,

Funded by NIAID.

oct. 2^nd, 2024

Preclinical Efficacy of Vaxxel’s Intranasal Vaccine Candidate Against Pneumovirus,

Funded by NIAID.

EN only

sept. 18^th, 2024

Brenus Pharma raises $25 million

To accelerate clinical trials of its precision cancer vaccines.

sept. 18^th, 2024

Brenus Pharma raises $25 million

To accelerate clinical trials of its precision cancer vaccines.

sept. 18^th, 2024

Brenus Pharma raises $25 million

To accelerate clinical trials of its precision cancer vaccines.

oct. 2^nd, 2024

New member : Imunys

They joined us !

oct. 2^nd, 2024

New member : Imunys

They joined us !

oct. 2^nd, 2024

New member : Imunys

They joined us !

sept. 18^th, 2024

New member : Kanēov

They joined us !

sept. 18^th, 2024

New member : Kanēov

They joined us !

sept. 18^th, 2024

New member : Kanēov

They joined us !

sept. 12^th, 2024

Osivax and KM Biologics enter exclusive License option agreement

for Broad-Spectrum “Universal” Influenza Vaccine in Japan.

sept. 12^th, 2024

Osivax and KM Biologics enter exclusive License option agreement

for Broad-Spectrum “Universal” Influenza Vaccine in Japan.

sept. 12^th, 2024

Osivax and KM Biologics enter exclusive License option agreement

for Broad-Spectrum “Universal” Influenza Vaccine in Japan.

EN only

sept. 5^th, 2024

ORIXHA obtains French Health Authority approval

to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome.

sept. 5^th, 2024

ORIXHA obtains French Health Authority approval

to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome.

sept. 5^th, 2024

ORIXHA obtains French Health Authority approval

to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome.

sept. 2^nd, 2024

New member : Injectys Technology

They joined us!

sept. 2^nd, 2024

New member : Injectys Technology

They joined us!

sept. 2^nd, 2024

New member : Injectys Technology

They joined us!

sept. 2^nd, 2024

New member : The Lépine Groupe

They joined us !

sept. 2^nd, 2024

New member : The Lépine Groupe

They joined us !

sept. 2^nd, 2024

New member : The Lépine Groupe

They joined us !

aug. 30^th, 2024

ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting

AdoShell® Islets is an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy and AdoGel® Sema a technology enabling the sustained release of semaglutide.

aug. 30^th, 2024

ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting

aug. 30^th, 2024

ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting

aug. 2^nd, 2024

Meddenovo Drug Design has completed the first closing of their pre-seed investment round

securing up to €1 million from ACT Venture Partners.

aug. 2^nd, 2024

Meddenovo Drug Design has completed the first closing of their pre-seed investment round

securing up to €1 million from ACT Venture Partners.

aug. 2^nd, 2024

Meddenovo Drug Design has completed the first closing of their pre-seed investment round

securing up to €1 million from ACT Venture Partners.

july 18^th, 2024

AstraZeneca Closes Acquisition of Amolyt Pharma

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline.

july 18^th, 2024

AstraZeneca Closes Acquisition of Amolyt Pharma

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline.

july 18^th, 2024

AstraZeneca Closes Acquisition of Amolyt Pharma

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline.

july 9^th, 2024

Axoltis Pharma announces the appointment of Jean-Guillaume Lafay

as a member of its Supervisory Board.

july 9^th, 2024

Axoltis Pharma announces the appointment of Jean-Guillaume Lafay

as a member of its Supervisory Board.

july 9^th, 2024

Axoltis Pharma announces the appointment of Jean-Guillaume Lafay

as a member of its Supervisory Board.

july 9^th, 2024

Nos membres ont la parole : Inserm Transfert

july 9^th, 2024

Nos membres ont la parole : Inserm Transfert

july 9^th, 2024

Nos membres ont la parole : Inserm Transfert

july 1^st, 2024

Carthera receives positive opinion from french high authority

sur le Forfait Innovation pour le traitement des patients atteints de glioblastome récurrent.

july 1^st, 2024

Carthera receives positive opinion from french high authority

sur le Forfait Innovation pour le traitement des patients atteints de glioblastome récurrent.

july 1^st, 2024

Carthera receives positive opinion from french high authority

sur le Forfait Innovation pour le traitement des patients atteints de glioblastome récurrent.

june 20^th, 2024

New Enosis Santé Chairman

Eric Vacaresse succeeds Christian Deleuze

june 20^th, 2024

New Enosis Santé Chairman

Eric Vacaresse succeeds Christian Deleuze

june 20^th, 2024

New Enosis Santé Chairman

Eric Vacaresse succeeds Christian Deleuze

june 13^th, 2024

New member : Cyrisbio

They joined us !

june 13^th, 2024

New member : Cyrisbio

They joined us !

june 13^th, 2024

New member : Cyrisbio

They joined us !

june 11^th, 2024

New member : EUNOVIS

They joined us !

june 11^th, 2024

New member : EUNOVIS

They joined us !

june 11^th, 2024

New member : EUNOVIS

They joined us !

june 7^th, 2024

Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia

Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated

june 7^th, 2024

Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia

Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated

june 7^th, 2024

Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia

Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated

june 4^th, 2024

ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer

In his new role, he will oversee Adocia’s operations and help accelerate its development and growth

june 4^th, 2024

ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer

In his new role, he will oversee Adocia’s operations and help accelerate its development and growth

june 4^th, 2024

ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer

In his new role, he will oversee Adocia’s operations and help accelerate its development and growth

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

may 16^th, 2024

APM : change of name

The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health.

may 16^th, 2024

APM : change of name

The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health.

may 16^th, 2024

APM : change of name

The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health.

april 17^th, 2024

MaaT Pharma Presents Positive 18-month Data for MaaT013

Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

april 17^th, 2024

MaaT Pharma Presents Positive 18-month Data for MaaT013

Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

april 17^th, 2024

MaaT Pharma Presents Positive 18-month Data for MaaT013

Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

april 10^th, 2024

Axoltis Pharma receives authorization to launch SEALS

Phase II clinical trial for ALS patients with drug candidate NX210c

april 10^th, 2024

Axoltis Pharma receives authorization to launch SEALS

Phase II clinical trial for ALS patients with drug candidate NX210c

april 10^th, 2024

Axoltis Pharma receives authorization to launch SEALS

Phase II clinical trial for ALS patients with drug candidate NX210c

april 10^th, 2024

Liquid ventilation: Orixha raises 4 million euros from the EIC Fund and Bpifrance

Total liquid Ventilation takes another step towards becoming a clinical reality

april 10^th, 2024

Liquid ventilation: Orixha raises 4 million euros from the EIC Fund and Bpifrance

Total liquid Ventilation takes another step towards becoming a clinical reality

april 10^th, 2024

Liquid ventilation: Orixha raises 4 million euros from the EIC Fund and Bpifrance

Total liquid Ventilation takes another step towards becoming a clinical reality

april 9^th, 2024

PDC*line Pharma presents interim clinical results

from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine etteurs

april 9^th, 2024

PDC*line Pharma presents interim clinical results

from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine etteurs

april 9^th, 2024

PDC*line Pharma presents interim clinical results

from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine etteurs

april 2^nd, 2024

Promega Research Shows Potential of Selective Degrade

Against Pediatric Cancer Cell Lines

april 2^nd, 2024

Promega Research Shows Potential of Selective Degrade

Against Pediatric Cancer Cell Lines

april 2^nd, 2024

Promega Research Shows Potential of Selective Degrade

Against Pediatric Cancer Cell Lines

march 14^th, 2024

Amolyt Pharma conclut un accord avec AstraZeneca

Definitive Agreement to be Acquired.

march 14^th, 2024

Amolyt Pharma conclut un accord avec AstraZeneca

Definitive Agreement to be Acquired.

march 14^th, 2024

Amolyt Pharma conclut un accord avec AstraZeneca

Definitive Agreement to be Acquired.

march 4^th, 2024

Promega Corporation and Eppendorf lead a study

to demonstrate the efficient expansion of human adipose-derived stem cells (hADSC) in stirred-tank bioreactors.

march 4^th, 2024

Promega Corporation and Eppendorf lead a study

to demonstrate the efficient expansion of human adipose-derived stem cells (hADSC) in stirred-tank bioreactors.

march 4^th, 2024

Promega Corporation and Eppendorf lead a study

to demonstrate the efficient expansion of human adipose-derived stem cells (hADSC) in stirred-tank bioreactors.

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

may 23^rd, 2024

New member : SYNTHELIS

They joined us !

march 4^th, 2024

MaaT Pharma Announces Positive Review on the Ongoing Phase 1 Clinical Trial

Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).

march 4^th, 2024

MaaT Pharma Announces Positive Review on the Ongoing Phase 1 Clinical Trial

Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).

march 4^th, 2024

MaaT Pharma Announces Positive Review on the Ongoing Phase 1 Clinical Trial

Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).

march 1^st, 2024

PK MED announces FDA clearance to initiate its clinical program

for PKM-01, for local treatment of gout flares, directly by a Phase 2 trial.

march 1^st, 2024

PK MED announces FDA clearance to initiate its clinical program

for PKM-01, for local treatment of gout flares, directly by a Phase 2 trial.

march 1^st, 2024

PK MED announces FDA clearance to initiate its clinical program

for PKM-01, for local treatment of gout flares, directly by a Phase 2 trial.

EN only

feb. 29^th, 2024

New member : VERSEVRAGE

They joined Lyonbiopole !

feb. 29^th, 2024

New member : VERSEVRAGE

They joined Lyonbiopole !

feb. 29^th, 2024

New member : VERSEVRAGE

They joined Lyonbiopole !

feb. 14^th, 2024

Stromacare nomme Georges Rawadi

au poste de Président.

feb. 14^th, 2024

Stromacare nomme Georges Rawadi

au poste de Président.

feb. 14^th, 2024

Stromacare nomme Georges Rawadi

au poste de Président.

EN only

feb. 5^th, 2024

GeNeuro announces a successful €5 million private placement

With cancellation of the preferential subscription rights through
an international private placement reserved for specialized or strategic investors.

feb. 5^th, 2024

GeNeuro announces a successful €5 million private placement

With cancellation of the preferential subscription rights through
an international private placement reserved for specialized or strategic investors.

feb. 5^th, 2024

GeNeuro announces a successful €5 million private placement

With cancellation of the preferential subscription rights through
an international private placement reserved for specialized or strategic investors.

feb. 1^st, 2024

Promega Corporation : a new publication in Nature Biomedical Engineering

featuring a collaboration between Promega and FDA.

feb. 1^st, 2024

Promega Corporation : a new publication in Nature Biomedical Engineering

featuring a collaboration between Promega and FDA.

feb. 1^st, 2024

Promega Corporation : a new publication in Nature Biomedical Engineering

featuring a collaboration between Promega and FDA.

jan. 26^th, 2024

Osivax appoints Dr. Nicola Groth as Chief Medical Officer

She brings over 25 years of experience in vaccine development.

jan. 26^th, 2024

Osivax appoints Dr. Nicola Groth as Chief Medical Officer

She brings over 25 years of experience in vaccine development.

jan. 26^th, 2024

Osivax appoints Dr. Nicola Groth as Chief Medical Officer

She brings over 25 years of experience in vaccine development.

EN only

jan. 25^th, 2024

HEPHAISTOS-Pharma secures a €2 million seed round

With xista science ventures, Foundation Fournier-Majoie and Noshaq.

jan. 25^th, 2024

HEPHAISTOS-Pharma secures a €2 million seed round

With xista science ventures, Foundation Fournier-Majoie and Noshaq.

jan. 25^th, 2024

HEPHAISTOS-Pharma secures a €2 million seed round

With xista science ventures, Foundation Fournier-Majoie and Noshaq.